Commentary on “A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy—A single-institution experience.”
Management of high-grade T1 (formerly T1G3) bladder cancer continues to be controversial. Should patients with T1G3 bladder cancer have an immediate radical cystectomy or should they receive intravesical bacillus Calmette-Gu érin preserving bladder? Gemcitabine and cisplatin (GC) adjuvant chemotherapy may help to strike a balance between intravesical and early cystectomy. For purposes of this study, we continue to refer high-grade T1 lesion as “T1G3.”
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: GL Yang, LH Zhang, Q Liu, ZL Wang, XH Duan, YR Huang, JJ. Bo Tags: Urologic Oncology Survey Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Study | Urology & Nephrology